Enrique Grande, One Oncology Madrid Program Director at Quironsalud, shared on X:
“Amazing rapid orals session in Neuroendocrine tumors at ESMO26!
Congratulations to the presenters and the discussants!
New Pb-based Radioligands and DLL3 driven drugs are promising new strategies in the field.”
You can also read:
KEYNOTE-365 Cohort I at ESMO 2026: Pembrolizumab Plus Chemotherapy in Neuroendocrine Prostate Cancer
